Eli Lilly and Company, Global Group Medical Director, Musculoskeletal Platform Team

Chemistry B.S., 1977
M.D., Indiana University, 1980

Dr. Sides received his undergraduate degree from Indiana State University in 1977, where he majored in chemistry. At ISU, Greg was an Indiana State University Academic Scholar, William P. Allyn Science Scholar, and an Earl Cooper Smith Chemistry Scholar.

He completed his first year of medical school at the Terre Center for Medical Education. He received his medical degree from Indiana University in 1980. From 1980-1983, he served an internship and residency in Internal Medicine at Methodist Hospital Indianapolis. He practiced emergency medicine in Indianapolis and Danville, Indiana from 1983 to 1988. He is boarded in both Internal Medicine and Emergency Medicine. He is a Fellow of both the American College of Physicians and the American College of Emergency Physicians.

He joined Eli Lilly and Company in 1988. At Lilly, Dr. Sides is responsible for developing new therapies for the treatment of disease. He has been involved in the development of both drugs and biologics. He and his group design global clinical trials to determine if new therapies are efficacious, safe, and cost effective. The group also prepares the registration dossiers, which are submitted to regulatory agencies worldwide.

Prior to his current position at Lilly, he served in various capacities including Global Medical Director of the Cialis Product Team, Medical Director of BioResearch Technologies and Proteins, and Director of Operations for Program Phase Medical. Dr. Sides led the clinical development of dirithromycin for respiratory and cutaneous infections. Dirithromycin is sold in 27 countries and was named Drug of the Year in 1994 by the Ministry of Health in Spain. Dr. Sides has also been involved in the development of anti-neutrophil antibodies, recombinant human hemoglobin, and anti-inflammatory drugs. He was responsible for the development, registration and approval of tadalafil, an erectile dysfunction drug. He currently is responsible for the clinical development of musculoskeletal drugs, in particular, drugs for the treatment of osteoporosis.

Dr. Sides has represented Lilly at numerous regulatory agencies including the U.S. Food and Drug Administration, the Health Protection Branch of Canada, the Medicines Control Agency of the U.K., Agencie du Medicament of France, der Bundestag fur Arzniemittel und Medizine of Germany, the Medicine Evaluation Board of the Netherlands, as well as other regulatory agencies.